Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC

NCT07398937 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

116

Enrollment

OTHER

Sponsor class

Conditions

Resectable Stage II-IIIa Squamous NSCLC

Interventions

DRUG: Serplulimab + chemotherapy
DRUG: Nivolumab + chemotherapy

Sponsor

Fudan University